The use of umbilical cord blood during allogeneic hematopoietic cell transplantation in children with malignant and non-malignant diseases of the blood system

Cover Page

Cite item

Abstract

Allogeneic hematopoietic stem cell transplantation [HSCT] is currently a generally accepted method of treating a significant number of oncological and non-malignant diseases. Every year the number of HSCs is increasing, and the list of pathologies that can be cured using this technique is also growing. Unfortunately, the probability of detecting an HLA-compatible related donor in the standard population does not exceed 25-30%. Despite the fact that the number of potential voluntary bone marrow donors included in international registries currently exceeds 9 million people, the probability of finding an HLA-identical unrelated donor for a patient belonging to the Caucasian race is 50-80%, while the time required for unrelated transplantation often exceeds 3-4 months [1]. To date, the level of early mortality in recipients of allogeneic HSCT is unacceptably high, which is associated with both the visceral toxicity of therapy [idiopathic pneumonitis, veno-occlusive liver disease] and with a variety of infections developing as a result of severe immunosuppression. In addition, allogeneic transplantation [primarily unrelated] is associated with a significant probability of developing a severe acute "graft-versus-host reaction" [oRTPH], which is the main cause of death of patients after HSCT.

Full Text

Restricted Access

About the authors

P. E. Trakhtman

FNCC of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: redaktor@celltranspl.ru
Russian Federation, Moscow

D. N. Balashov

FNCC of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation

Email: redaktor@celltranspl.ru
Russian Federation, Moscow

I. L. Shchipitsyna

FNCC of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation

Email: redaktor@celltranspl.ru
Russian Federation, Moscow

O. L. Blagonravova

FNCC of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation

Email: redaktor@celltranspl.ru
Russian Federation, Moscow

Z. M. Dyshleva

FNCC of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation

Email: redaktor@celltranspl.ru
Russian Federation, Moscow

E. V. Skorobogatova

FNCC of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation

Email: redaktor@celltranspl.ru
Russian Federation, Moscow

E. E. Kournikova

FNCC of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation

Email: redaktor@celltranspl.ru
Russian Federation, Moscow

A. A. Maschan

FNCC of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation

Email: redaktor@celltranspl.ru
Russian Federation, Moscow

A. G. Rumyantsev

FNCC of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation

Email: redaktor@celltranspl.ru
Russian Federation, Moscow

References

  1. Armitage J. Medical progress: bone marrow transplantation. N. Eng. J. Med. 1994:330: 827-38.
  2. Knudtzon S. In vitro growth of granulocytic colonies from circulating cells in human cord blood. Blood 1974; 43: 357-61.
  3. BroxmeyerH.E., Douglas G.W., HangocG. et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc. Natl. Acad. Sci. USA 1989; 86: 3828-32.
  4. Christensen R.D., Harper T.E., Rothstein G. Granulocytemacrophage progenitor cells in term and preterm neonates. J. Pediatr. 1986; 109:1047-51.
  5. NakahataT., Ogawa M. Hemopoietic colony-forming cells in umbilical cord blood with extensive capability to generate mono- and multi potential hemopoietic progenitors. J. Clin. Invest. 1982; 70:1324-8.
  6. Han P„ Hodge G., Story C. et al. Phenotypic analysis of functional T-lymphocyte subtypes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation. Br. J. Haematol. 1995; 89: 733-40.
  7. Cardoso A.A., Li M.L., Batard P. et al. Human umbilical cord blood CD34+ cell purification with high yield of early progenitors. J. Hematother. 1993; 2: 275-9.
  8. Broxmeyer H.E., Hangoc G., Cooper S. et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc. Natl. Acad. Sci. USA 1992; 89: 4109-13.
  9. Rubinstein P., Dobrila L., Rosenfield R.E. et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc. Natl. Acad. Sci. USA 1995; 92:10119-22.
  10. Gluckman E., Broxmeyer H.A., Auerbach A.D. et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N. Engl. J. Med. 1989; 321:1174-8.
  11. Wernet P. The Netcord inventory and use [Netcord web site], https:// www.netcord.org/inventory.gif.
  12. Wagner J.E., Kernan N.A., Steinbuch M. et al. Allogeneic sibling umbilical- cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346: 214-9.
  13. Gluckman Е. Current status of umbilical cord blood hematopoietic stem cells transplantation. Exp. Hematol. 2000; 28:1197-205.
  14. Barker J.N., Davies S.M., DeFor T. et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97: 2957-61.
  15. Rocha V., Chastang C., Souillet G. et al. Related cord blood transplants: the Eurocord experience from 78 transplants. Eurocord Transplant Group. Bone Marrow Transplant. 1998; 21 [Suppl. 3): S59-S62.
  16. Gluckman E., Rocha V., Boyer-Chammard A. et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N. Engl. J. Med. 1997;337:373-81.
  17. Rocha V., Wagner J.E. Jr, Sobocinski K.A. et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N. Engl. J. Med. 2000; 342:1846-54.
  18. Gluckman E., Rocha V., Chevret S. et al. Factors associated with outcome if unrelated cord blood transplant: guidelines for donor choice. An. Eurocord study. Blood 2002; 100 [Suppl. 1): 642a.

Copyright (c) 2023 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 57156 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies